Company Overview
Company Type: Private Company
Website: abkbiomedical.com
Number of Employees: -
Year Founded: 2012
Total Amount Raised (CAD mm)†: 82.84
Total Rounds of Funding**:3
Latest Post-Money Valuation ($ mm) -
Latest Pre-Money Valuation ($ mm) -
† This number reflects the estimated value of the total new money raised through private placement rounds.
** This value is an estimate of the total number of funding rounds this company has received.


Business Description
ABK Biomedical Inc. engages in research and development of medical device therapies to improve treatment outcomes and the lives of patients with liver tumors. Its products include Eye90 microspheres, a novel technology for Y90 radioembolization with a proprietary and imageable glass composition for in-procedure visualization; and Easi-Vue embolic microspheres, and imageable bland embolization product allowing direct visualization at the target site. The company was incorporated in 2012 and is based in Halifax, Canada with an additional location in Ladera Ranch, California.


Financial Information (Currency: CAD, in mm)
Total Revenue
-
Operating Income
-
Total Assets
-
Gross Profit
-
EBITDA
-
Total Debt
-
Net Income
-
Estimated Number of Employees
-
Net Debt
-
* Hover over data point numbers for date and source.

Key Professionals
Name
Title
Mangano, Michael 
President, CEO & Director
Abraham, Bob
Co-Founder
Kehoe, Sharon
Co-Founder
Tyson, Mike 
Chief Financial Officer
Arepally, Aravind 
Chief Medical Officer
Donofrio, Gary 
Chief Business Officer

Key Board Members
Name
Title
Berez, Aaron L.
Chairman
Mangano, Michael 
President, CEO & Director
Black, Carissa Bellardine
Director
Eadie, James 
Director
McLaren, James Ian
Director
Patel, Ketan 
Director
Sharma, Ricky 
Director


Primary Industry Classification
Health Care Equipment


Primary Office Location
155 Chain Lake Drive Unit 32 | Halifax, NS | B3S 1B3 | Canada
Phone: 902 442 4009   

Current and Pending Investors
Investor
Initial Investment Date
Stake Type
Current Stake Amount
Round(s)
Eight Roads Ventures
Sep-09-2022
Unknown
-
Series C
Santé Ventures, LLC
Sep-09-2022
Minority
-
Series C
Impresa Management LLC
Apr-08-2019
Minority
-
Series B
Varian Medical Systems, Inc.
Apr-08-2019
Minority
-
Series B
Invest Nova Scotia
Oct-22-2012
Unknown
-
Venture


Company Notes
No Company Notes exist.


Strategy Notes
No Strategy Notes exist.


Last 5 Transactions
Announced Date
Closed Date
Transaction Type
Role
Target
Buyer/Investors
Sellers
Size($mm)
Sep-09-2022
Dec-06-2022
Private Placement
Target
ABK Biomedical Inc.
Impresa Management LLC,Santé Ventures, LLC,Eight Roads Ventures

30.00
Apr-08-2019
Apr-08-2019
Private Placement
Target
ABK Biomedical Inc.
Varian Medical Systems, Inc.,Impresa Management LLC

30.00
Oct-22-2012
Oct-22-2012
Private Placement
Target
ABK Biomedical Inc.
Invest Nova Scotia

0.75
* denotes that the relationship is proprietary


Last 5 Key Developments
Date
Event Type
Headline
May-30-2023
Product-Related Announcements
ABK Biomedical Inc. Announces FDA IDE Approval for a Multi-Center Pivotal Study of Eye90 microspheres® in Hepatocellular Carcinoma
Dec-06-2022
Private Placements
ABK Biomedical Inc. announced that it has received $30 million in funding from Santé Ventures, LLC, Impresa Management LLC, Eight Roads Ventures and others
Sep-12-2022
Product-Related Announcements
ABK Biomedical Inc. Announces FDA 510(K) Clearance of Easi-Vue Embolic Microspheres for the Embolization of Arteriovenous Malformations and Hypervascular Tumors
Sep-09-2022
Private Placements
ABK Biomedical Inc. announced that it expects to receive $18.08668 million in funding from Santé Ventures, LLC, Impresa Management LLC, Eight Roads Ventures
Apr-19-2022
Product-Related Announcements
ABK Biomedical Announces First Patient Treated in First-in-Human Clinical Study with Eye90 Microspheres for Treatment of Liver Tumors


Last 10 Investment Research Documents
No Investment Research returned. This can be caused by entitlement settings or your template settings.


S&P Global Ratings Credit Ratings
No S&P Global Ratings Credit Ratings data available. 


News Headlines
No News is currently available for the selected sources.


Company Coverage
This company is not on any Coverage List.

Key Board Members Details
Name
Title
Phone
Fax
Email
Berez, Aaron L.
Chairman
902 442 4009
-

Mangano, Michael 
President, CEO & Director
902 442 4009
-

Black, Carissa Bellardine
Director
902 442 4009
-

Eadie, James 
Director
902 442 4009
-
james.eadie@santeventures.com
McLaren, James Ian
Director
902 442 4009
-

Patel, Ketan 
Director
(617) 231-2400
(617) 231-2425

Sharma, Ricky 
Director
902 442 4009
-

* denotes that the relationship is proprietary

Key Executives and Professionals Details
Name
Title
Phone
Fax
Email
Mangano, Michael 
President, CEO & Director
902 442 4009
-

Abraham, Bob
Co-Founder
902 442 4009
-
-
Kehoe, Sharon
Co-Founder
902 442 4009
-
-
Tyson, Mike 
Chief Financial Officer
902 442 4009
-

Arepally, Aravind 
Chief Medical Officer
902 442 4009
-

Donofrio, Gary 
Chief Business Officer
902 442 4009
-

* denotes that the relationship is proprietary

S&P Credit Ratings and Research provided by 
No content (including ratings, credit-related analyses and data, valuations, model, software or other application or output therefrom) or any part thereof (Content) may be modified, reverse engineered, reproduced or distributed in any form by any means, or stored in a database or retrieval system, without the prior written permission of S&P Global Market Intelligence or its affiliates (collectively, S&P Global). The Content shall not be used for any unlawful or unauthorized purposes. S&P Global and any third-party providers, as well as their directors, officers, shareholders, employees or agents (collectively S&P Global Parties) do not guarantee the accuracy, completeness, timeliness or availability of the Content. S&P Global Parties are not responsible for any errors or omissions (negligent or otherwise), regardless of the cause, for the results obtained from the use of the Content, or for the security or maintenance of any data input by the user. The Content is provided on an "as is" basis. S&P GLOBAL PARTIES DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING, BUT NOT LIMITED TO, ANY WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE, FREEDOM FROM BUGS, SOFTWARE ERRORS OR DEFECTS, THAT THE CONTENT’S FUNCTIONING WILL BE UNINTERRUPTED OR THAT THE CONTENT WILL OPERATE WITH ANY SOFTWARE OR HARDWARE CONFIGURATION. In no event shall S&P Global Parties be liable to any party for any direct, indirect, incidental, exemplary, compensatory, punitive, special or consequential damages, costs, expenses, legal fees, or losses (including, without limitation, lost income or lost profits and opportunity costs or losses caused by negligence) in connection with any use of the Content even if advised of the possibility of such damages.

Credit-related and other analyses, including ratings, and statements in the Content are statements of opinion as of the date they are expressed and not statements of fact. S&P Global Market Intelligence’s opinions, analyses and rating acknowledgment decisions (described below) are not recommendations to purchase, hold, or sell any securities or to make any investment decisions, and do not address the suitability of any security. S&P Global Market Intelligence assumes no obligation to update the Content following publication in any form or format. The Content should not be relied on and is not a substitute for the skill, judgment and experience of the user, its management, employees, advisors and/or clients when making investment and other business decisions. S&P Global Market Intelligence does not act as a fiduciary or an investment advisor except where registered as such. While S&P Global Market Intelligence has obtained information from sources it believes to be reliable, S&P Global Market Intelligence does not perform an audit and undertakes no duty of due diligence or independent verification of any information it receives.

S&P Global keeps certain activities of its divisions separate from each other in order to preserve the independence and objectivity of their respective activities. As a result, certain divisions of S&P Global may have information that is not available to other S&P Global divisions. S&P Global has established policies and procedures to maintain the confidentiality of certain non-public information received in connection with each analytical process.

S&P Global Ratings does not contribute to or participate in the creation of credit scores generated by S&P Global Market Intelligence. Lowercase nomenclature is used to differentiate S&P Global Market Intelligence PD credit model scores from the credit ratings issued by S&P Global Ratings.

S&P Global may receive compensation for its ratings and certain analyses, normally from issuers or underwriters of securities or from obligors. S&P Global reserves the right to disseminate its opinions and analyses. S&P Global's public ratings and analyses are made available on its Web sites, www.standardandpoors.com (free of charge), and www.capitaliq.com (subscription), and may be distributed through other means, including via S&P Global publications and third-party redistributors. Additional information about our ratings fees is available at www.standardandpoors.com/usratingsfees.
Regulatory News Service data provided by 
